NCT05027529Completed
ECMOsorb Trial - Impact of a VA-ECMO in Combination With CytoSorb in Critically Ill Patients With Cardiogenic Shock
ECMOsorb Trial - Impact of a VA-ECMO in Combination With CytoSorb in Critically Ill Patients With Cardiogenic Shock- A Prospective, Randomized, Blinded, Monocenter Trial.
Source: ClinicalTrials.gov · Last updated 4 Feb 2026
Brief summary (registry, in English)
In the ECMOsorb study the impact of a veno-arterial -ECMO in combination with an extracorporeal cytokine hemadsorption system in critically ill patients with cardiogenic shock is to be examined
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 42 (actual)
- First submitted
- 12 Mar 2021
- Start date
- 21 May 2021
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Christian Schulze
- Diseases
- Heart failure
- NCT number
- NCT05027529
What you commit to
- Study type: Interventional
- Participants enrolled: 42
- From 21 May 2021 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current immunosuppressive or immunomodulatory therapy
- Severe concomitant disease with limited life expectancy \<6 months.
Other illness
- Severe PVD (peripheral vessel disease) making ECMO-implantation impossible.
- Aortic valve insufficiency / stenosis at least II °.
- CNS disease with fixed, dilated pupils (not drug-induced).
Lab values
- Very low platelet counts (\< 20,000/µl)
Age
- Age \> 80 years.
Other
- Current participation in another interventional trial
- Pregnancy
- Contraindications to VA-ECMO implantation.
- Patients with pre - existing sepsis (raised CPR, positive PCT, leukozytosis, fever, positive blood cultures).
- Shock duration\> 12 h before evaluation.
- CPR\> 60min.
- Shock due to other reasons
- HIT positive (Heparin induced thrombocytopenia)
- Body weight less than 45 kg
Who the study is looking for
- Cardiogenic shock of any cause and indication for VA-ECMO
- Age between 18 and 80
- Signed informed consent
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Jena University Hospital, Department of Cardiology Coordinator of this site? Confirm its status | Jena | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.